Biofrontera Inc.
BFRIHealthcare|Medical - Pharmaceuticals|US
$0.83
+0.02 (+2.50%)
Tangible Book / Share
$0.26
Cash / Share
$0.36
About
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Stock Price
-28.6%(1Y)
1M
-9.9%
3M
-34.8%
6M
-28.0%
YTD
+45.3%
1Y
-20.4%
3Y
-80.0%
5Y
-98.7%
Pipeline Summary
15 total trials3
Phase 1
4
Phase 2
6
Phase 3
2
Phase 4
Completed: 11Unknown: 2Active: 2
Active Trials (2)
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
NCT03573401Superficial Basal Cell Carcinoma
Phase 3Active
Enrollment: 187 participants
Cryotherapy in Combination With Red Light PDT for Actinic Keratosis of Full Face
NCT06745999Actinic Keratoses
Phase 4Active
Enrollment: 40 participants
Key Facts
Market Cap$12.3M
Employees72 (-22% YoY)
CEOHermann Lübbert
IPO DateOct 29, 2021
Beta0.90
52-Week Range$0.5547 – $1.66
Avg Volume463,445
ExchangeNASDAQ
Websitebiofrontera-us.com
Ownership
Float86.5%
Shares Outstanding14.9M
Recent Insider Trades
Luebbert HermannOPTION EX.
Jul 28, 202662,500 shares
Luebbert HermannOPTION EX.
Jul 28, 202662,500 shares
Leffler Eugene FrederickOPTION EX.
Jul 28, 202631,250 shares
Leffler Eugene FrederickOPTION EX.
Jul 28, 202631,250 shares
Weber Kevin DanielAWARD
Mar 4, 202620,000 shares @ $0.90
Peers
Recent News
Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
Nov 6, 2026 · globenewswire.com
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
Oct 8, 2026 · globenewswire.com
Biofrontera (NASDAQ:BFRI) & Astrazeneca (NYSE:AZN) Critical Contrast
Oct 5, 2026 · defenseworld.net
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
Sep 14, 2026 · globenewswire.com
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Aug 13, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 03:59 AM